PAR reports consistent pain reduction in knee OA of patients
Filed with ASX · · 4 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- PAR corrects AFR article
- Successful Completion of Retail Entitlement Offer
- Paradigm Corporate Update - May 2019
- Quarterly Report and Appendix 4C - quarterly
- Completion of Institutional Entitlement Offer
Later from Paradigm Biopharmaceuticals
- PAR reports successful Ross River phase 2 clinical trial
- Paradigm EOFY Update
- Appendix 4C - quarterly
- Paradigm files first IND with US FDA
- PARs drug reduces cartilage degradation in subjects with OA
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals